Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment

American Journal of Physiology - Endocrinology and Metabolism

Volumn 304, Issue 2, 2013, Pages

  Dong, Zhenhua ^a,b   Chai, Weidong ^a   Wang, Wenhui ^b   Zhao, Lina ^a   Fu, Zhuo ^a   Cao, Wenhong ^c   Liu, Zhenqi ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c The University of North Carolina at Chapel Hill   (United States)

Author keywords

Glucagon like peptide 1; Microvascular recruitment; Nitric oxide; Protein kinase A

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NITRIC OXIDE; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BLOOD VOLUME; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; EX VIVO STUDY; HINDLIMB; LEG MUSCLE; MALE; MEDIATOR; MICROVASCULARIZATION; MUSCLE BLOOD FLOW; MUSCLE BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SAPHENOUS ARTERY; SAPHENOUS VEIN; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CATTLE; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GLUCAGON-LIKE PEPTIDE 1; INSULIN; MALE; MICROVESSELS; MUSCLE, SKELETAL; NITRIC OXIDE; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW;

EID: 84872407467     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00473.2012     Document Type: Article

References (41)

1. Acitores A, González N, Sancho V, Valverde I, Villanueva-Peñacarrillo ML. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J Endocrinol 180: 389-398, 2004.
2. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150: 1155-1164, 2009.
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157, 2007.
4. Barrett E, Eggleston E, Inyard A, Wang H, Li G, Chai W, Liu Z. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 52: 752-764, 2009.
5. Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab 301: E252-E263, 2011.
6. Boo YC, Hwang J, Sykes M, Michell BJ, Kemp BE, Lum H, Jo H. Shear stress stimulates phosphorylation of eNOS at Ser635 by a protein kinase A-dependent mechanism. Am J Physiol Heart Circ Physiol 283: H1819-H1828, 2002.
7. Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic b-cell mass. Diabetes 55: 1190-1196, 2006.
8. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61: 888-896, 2012.
9. Chai W, Wang W, Dong Z, Cao W, Liu Z. Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo. Diabetes 60: 2939-2946, 2011.
10. Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, Liu Z. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension 55: 523-530, 2010.
11. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265: 5267-5272, 1990.
12. Clark MG. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. Am J Physiol Endocrinol Metab 295: E732-E750, 2008.
13. Dixit M, Loot AE, Mohamed A, Fisslthaler B, Boulanger CM, Ceacareanu B, Hassid A, Busse R, Fleming I. Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress. Circ Res 97: 1236-1244, 2005.
14. Drucker DJ. The biology of incretin hormones. Cell Metab 3: 153-165, 2006.
15. Erdogdu Ö, Nathanson D, Sjöholm Å, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325: 26-35, 2010.
16. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 102: 81-86, 2001.
17. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478: 136-142, 2008.
18. Hallbrink M, Holmqvist T, Olsson M, Ostenson CG, Efendic S, Langel U. Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Gas and Gai/Gao activation. Biochim Biophys Acta 1546: 79-86, 2001.
19. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, Hayashi T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53: 2256-2263, 2010.
20. Heijnen HF, Waaijenborg S, Crapo JD, Bowler RP, Akkerman JW, Slot JW. Colocalization of eNOS and the catalytic subunit of PKA in endothelial cell junctions: A clue for regulated NO production. J Histochem Cytochem 52: 1277-1285, 2004.
21. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439, 2007.
22. Honig CR, Odoroff CL, Frierson JL. Active and passive capillary control in red muscle at rest and in exercise. Am J Physiol Heart Circ Physiol 243: H196-H206, 1982.
23. Johannes FJ, Prestle J, Dieterich S, Oberhagemann P, Link G, Pfizenmaier K. Characterization of activators and inhibitors of protein kinase C+. Eur J Biochem 227: 303-307, 1995.
24. Ko SH, Cao W, Liu Z. Hypertension management and microvascular insulin resistance in diabetes. Curr Hypertens Rep 12: 243-251, 2010.
25. Li G, Barrett EJ, Ko SH, Cao W, Liu Z. Insulin and insulin-like growth factor-I receptors differentially mediate insulin-stimulated adhesion molecule production by endothelial cells. Endocrinology 150: 3475-3482, 2009.
26. Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 146: 4690-4696, 2005.
27. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60: 833-841, 2012.
28. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 24: 261-274, 2006.
29. Marunaka Y, Niisato N. H89, an inhibitor of protein kinase A (PKA), stimulates Na+ transport by translocating an epithelial Na+ channel (ENaC) in fetal rat alveolar type II epithelium. Biochem Pharmacol 66: 1083-1089, 2003.
30. Michell BJ, Chen ZP, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276: 17625-17628, 2001.
31. Michell BJ, Harris MB, Chen ZP, Ju H, Venema VJ, Blackstone MA, Huang W, Venema RC, Kemp BE. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem 277: 42344-42351, 2002.
32. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961, 2004.
33. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408, 2005.
34. Nystrom T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 40: 593-606, 2008.
35. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287: E1209-E1215, 2004.
36. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen speciesinduced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 30: 1407-1414, 2010.
37. Puana R, McAllister RK, Hunter FA, Warden J, Childs EW. Morphine attenuates microvascular hyperpermeability via a protein kinase A-dependent pathway. Anesth Analg 106: 480-485, 2008.
38. Richter G, Feddersen O, Wagner U, Barth P, Göke R, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol Lung Cell Mol Physiol 265: L374-L381, 1993.
39. Schaap P, van Ments-Cohen M, Soede RD, Brandt R, Firtel RA, Dostmann W, Genieser HG, Jastorff B, van Haastert PJ. Cell-permeable non-hydrolyzable cAMP derivatives as tools for analysis of signaling pathways controlling gene regulation in Dictyostelium. J Biol Chem 268: 6323-6331, 1993.
40. Wang N, Ko SH, Chai W, Li G, Barrett EJ, Tao L, Cao W, Liu Z. Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNF. Am J Physiol Endocrinol Metab 300: E195-E201, 2011.
41. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317: 1106-1113, 2006.